Insmed Incorporated
Trade Insmed Incorporated 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About INSM
Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline.
INSM Key Statistics
Stock Snapshot
With a market cap of 23.2B, Insmed Incorporated(INSM) trades at $108.40. The stock has a price-to-earnings ratio of -18.63.
During the trading session on 2026-07-21, Insmed Incorporated(INSM) shares reached a daily high of $108.40 and a low of $108.40. At a current price of $108.40, the stock is 0.0% higher than the low and still 0.0% under the high.
Trading activity shows a volume of 260, compared to an average daily volume of 2.42M.
Over the past 52 weeks, Insmed Incorporated(INSM) stock has traded between a high of $212.75 and a low of $90.39.
Over the past 52 weeks, Insmed Incorporated(INSM) stock has traded between a high of $212.75 and a low of $90.39.
INSM News
...
BMO Capital analyst Conor MacKay initiated coverage of Insmed (INSM) with an Outperform rating and $192 price target The firm’s positive view is based on Brinsu...
Analyst Maxwell Skor from Morgan Stanley maintained a Buy rating on Insmed and keeping the price target at $212.00. TipRanks has entered a new arena in the inv...
Analyst ratings
100%
of 25 ratingsMore INSM News
TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE. R...
Analyst Jason Zemansky from Bank of America Securities maintained a Buy rating on Insmed and keeping the price target at $214.00. TipRanks has entered a new ar...
PAH is a rare, progressive disease where the tiny arteries in the lungs narrow, increasing blood pressure and forcing the heart to work harder. Sustained Effic...
Insmed (INSM) announced positive 12-Month data from the ongoing open-label extension study evaluating treprostinil palmitil inhalation powder, or TPIP, administ...
Wells Fargo raised the firm’s price target on Insmed (INSM) to $161 from $160 and keeps an Overweight rating on the shares. The stock appears oversold on Brinsu...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.